ClinicalTrials.gg
CompletedNCT03802344Updated Dec 16, 2020Results posted

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

A Phase 3 interventional study of MC2-01 cream and Cal/BDP combination in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by MC2 Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
14th of 47
498 · median 200
Started
2018
with 2 others
Phase 3
17 of 47
none open now
Registered
36th of 47
by date
Lead sponsor
4 of 47
MC2 Therapeutics

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 14th largest by enrollment, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 36th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.

Read the detailed description

The MC2-01 Cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. In this trial, the MC2-01 cream will be compared to a marketed product CAL/BDP combination and vehicle. The purpose of the trial is to compare the clinical efficacy, safety, and convenience of this cream to the marketed product. The trial will include a 8-week treatment period.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have provided written
  • Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening
  • Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment with a maximum of 15 g of trial medication per day
  • Have a PGA of disease severity of mild or moderate on the body (trunk and/or limbs)
  • Have an mPASI score of at least 3
  • Have a treatment area involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of unstable forms of psoriasis
  • Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris
  • Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
  • Planned excessive or prolonged exposure to either natural or artificial sunlight
  • History of to any component of the test product or reference product
  • Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
  • Systemic treatment with biological therapies
  • Use of systemic treatments that suppress the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to Visit 1/Baseline and during the trial
  • Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial
  • Use of topical treatments except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline
  • Presence of infections in the treatment area (bacteria, viruses, parasites or fungi) or skin manifestations of atrophic skin, atrophic striae, skin vein fragility, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wound in the treatment area
  • Known (HIV) infection
  • Have any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial
  • Initiation of, or expected changes to, concomitant medication that may affect psoriasis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    MC2-01 Cream

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks

    Drug: MC2-01 cream

  • Active comparator
    Cal/BDP combination

    Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks

    Drug: Cal/BDP combination

  • Placebo comparator
    Vehicle

    One application daily for 8 weeks

    Drug: Vehicle

Interventions

  • DrugMC2-01 cream

    Drug pages: Calcipotriene · Betamethasone dipropionate

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

  • DrugCal/BDP combination

    Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%

  • DrugVehicle

    Vehicle cream

06

What researchers measure

Primary outcomes

  1. Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score

    The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at the 3 areas for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100 (if a reduction is seen the value will be presented as a negative number)

    Time frame: 8 Weeks

Secondary outcomes

  1. The Psoriasis Treatment Convenience Scale (PTCS)

    PTCS measures the impact and convenience of the treatment. The scale consists of 6 disease-specific questions, which individually will be rated on a 1-10 points scale, where a score of 1 represents the lowest satisfactory response with the treatment and 10 represents the highest satisfactory response. The questions are: Q1. How easy was the treatment to apply to the skin?; Q2. How greasy was the treatment when applying it to the skin?; Q3. How moisturized did your skin feel after apolying the treatment?; Q4. How greasy did your skin feel after applying the treatment?; Q5. How much did treating you skin disrupt your daily routine?; Q6. Overall, how satisfied were you with the medical treatment? The total PTCS score is calculated as the sum of the first 5 questions, ranging from 5 \[low satisfaction\] to 50 \[high satisfaction\].

    Time frame: 8 Weeks

07

Results

Posted Nov 27, 2020

Participant flow

First Subject First Visit: 12-Dec-2018. Last Subject Last Visit: 02-Oct-2019.

Participant flow — Overall Study
MilestoneMC2-01 CreamCal/BDP CombinationVehicle
Started21320968
Completed20520355
Not completed8613

Outcome measures

PrimaryPercentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score

The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at the 3 areas for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100 (if a reduction is seen the value will be presented as a negative number)

Time frame:
8 Weeks
Reported as:
Mean · Percentage change from Baseline
Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score
Percentage change from BaselineMC2-01 CreamCal/BDP CombinationVehicle
Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score-67.5 ± 20.8-63.5 ± 22.2-11.7 ± 21.9
SecondaryThe Psoriasis Treatment Convenience Scale (PTCS)

PTCS measures the impact and convenience of the treatment. The scale consists of 6 disease-specific questions, which individually will be rated on a 1-10 points scale, where a score of 1 represents the lowest satisfactory response with the treatment and 10 represents the highest satisfactory response. The questions are: Q1. How easy was the treatment to apply to the skin?; Q2. How greasy was the treatment when applying it to the skin?; Q3. How moisturized did your skin feel after apolying the treatment?; Q4. How greasy did your skin feel after applying the treatment?; Q5. How much did treating you skin disrupt your daily routine?; Q6. Overall, how satisfied were you with the medical treatment? The total PTCS score is calculated as the sum of the first 5 questions, ranging from 5 \[low satisfaction\] to 50 \[high satisfaction\].

Time frame:
8 Weeks
Reported as:
Mean · score on a scale
The Psoriasis Treatment Convenience Scale (PTCS)
score on a scaleMC2-01 CreamCal/BDP CombinationVehicle
The Psoriasis Treatment Convenience Scale (PTCS)38.6 ± 6.236.1 ± 7.036.2 ± 7.6

Adverse events

Collected over AEs were collected/assessed from the time of the signature of the informed consent form by the subject and until the end of the trial, i.e. until the Follow-up visit at Week 10. AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the subject was stable.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MC2-01 Cream0/213 (0%)1/213 (0.5%)10/213 (4.7%)
Cal/BDP Combination0/209 (0%)3/209 (1.4%)11/209 (5.3%)
Vehicle0/68 (0%)1/68 (1.5%)1/68 (1.5%)
Most frequent serious events
Most frequent serious events
EventMC2-01 CreamCal/BDP CombinationVehicle
Cholesystitis acuteGastrointestinal disorders0/2130/2091/68
Herpes zoster meningitisInfections and infestations0/2131/2090/68
Humerus fractureMusculoskeletal and connective tissue disorders0/2131/2090/68
Pulmonary tuberculosisInfections and infestations0/2131/2090/68
Testicular seminomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2130/2090/68
Most frequent other events
Most frequent other events
EventMC2-01 CreamCal/BDP CombinationVehicle
NasopharyngitisInfections and infestations10/21311/2091/68

Baseline characteristics

Age, Continuous
Age, Continuous(years)MC2-01 CreamCal/BDP CombinationVehicleTotal
Mean48.6 ± 13.751.5 ± 14.850.8 ± 13.150.2 ± 14.02
Sex: Female, Male
Sex: Female, Male(Participants)MC2-01 CreamCal/BDP CombinationVehicleTotal
Female779622195
Male13611346295
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MC2-01 CreamCal/BDP CombinationVehicleTotal
Hispanic or Latino0000
Not Hispanic or Latino21320968490
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MC2-01 CreamCal/BDP CombinationVehicleTotal
Race — White21120565481
Race — Black or African American0022
Race — Asian1203
Race — Gipsy1102
Race — North African0112
Region of Enrollment
Region of Enrollment(participants)MC2-01 CreamCal/BDP CombinationVehicleTotal
Czechia646320147
Germany949030214
Poland555618129
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)MC2-01 CreamCal/BDP CombinationVehicleTotal
I6208
II10410329236
III777625178
IV2019948
V67518
VI0202
08

Study locations

2 sites
  • Dermatovenerologie a korektivní dermatologie
    Praha 1, Těšnov 1163/5 110 00, Czechia
  • University Medical Center Hamburg
    Hamburg, 20246, Germany
09

References and documents

Publications

  • Praestegaard M, Steele F, Crutchley N. Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application. Dermatol Ther (Heidelb). 2022 Oct;12(10):2217-2231. doi: 10.1007/s13555-022-00794-y. Epub 2022 Sep 1. PubMed 36050567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Oct 2019, 9 months.

Results were first posted in Nov 2020, 1 year 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Jan 14, 2019
StartActual
Dec 12, 2018
Primary completionActual
Oct 2, 2019
CompletionActual
Oct 2, 2019
Results first posted
Nov 27, 2020
Last update
Dec 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03802344
Lead sponsor
MC2 Therapeutics
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Dec 12, 2018
Primary completion
Oct 2, 2019
Completion
Oct 2, 2019
Results posted
Nov 27, 2020
Last update
Dec 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion